Heron Therapeutics Announces Filing of an Efficacy Supplement for ZYNRELEF® and Provision in Newly Passed Congressional Bill Anticipated to Provide Separate Reimbursement Outside of the Packaged Surgical Payment for ZYNRELEFPRNewsWire • 12/29/22
Heron Therapeutics Announces Virtual Presentation at Evercore ISI 5th Annual HealthCONx ConferencePRNewsWire • 11/21/22
Heron Therapeutics (HRTX) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/09/22
Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2022 and Highlights Recent Corporate UpdatesPRNewsWire • 11/08/22
Heron Therapeutics to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022PRNewsWire • 11/01/22
Heron Therapeutics Announces U.S. FDA Approval of APONVIE™ (HTX-019) for the Prevention of Postoperative Nausea and Vomiting (PONV)PRNewsWire • 09/16/22
All You Need to Know About Heron Therapeutics (HRTX) Rating Upgrade to BuyZacks Investment Research • 08/23/22
How Much Upside is Left in Heron Therapeutics (HRTX)? Wall Street Analysts Think 91%Zacks Investment Research • 08/15/22
Heron Therapeutics, Inc.'s (HRTX) CEO Barry Quart on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/09/22
Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2022 and Highlights Recent Corporate UpdatesPRNewsWire • 08/09/22
Heron Therapeutics to Report Second Quarter 2022 Financial Results on Tuesday, August 9, 2022PRNewsWire • 08/02/22
Heron Therapeutics to cut about one-third of its workforce as part of cost-cutting planMarket Watch • 06/30/22
Heron Therapeutics Announces Restructuring and Cost Reduction Plan to Address Market Dynamics and Prepare for Long-Term SustainabilityPRNewsWire • 06/30/22
Heron Therapeutics Announces Publication Showing ZYNRELEF® as the Foundation of a Perioperative Non-Opioid Multimodal Analgesic Regimen Reduced Severe Pain and Opioid Use in Patients Undergoing Total Knee ArthroplastyPRNewsWire • 06/14/22